David Melnick
Analyst
Consultant and Senior Clinical Advisor
Equibles does not estimate personal net worth.
About David Melnick
David Melnick is recorded as Analyst at Consultant and Senior Clinical Advisor. The proxy statement of Spero Therapeutics, Inc. reports total compensation of $999,913 for David Melnick in fiscal 2020, including a base salary of $411,450. Disclosed compensation is on record for 3 fiscal years. David Melnick has spoken on 1 earnings call across 1 company, most recently for Spero Therapeutics, Inc. on March 11, 2021. The companies whose calls David Melnick spoke on are classified in the Healthcare sector.
David Melnick on recent calls
“I'm very happy to share our pipeline updates today. Let me begin with our lead candidate tebipenem HBr, an oral carbapenem for which we've reported positive Phase 3 data in September.”
Affiliation history
-
Consultant and Senior Clinical Advisor
Analyst
Source not stated
Current -
Spero Therapeutics, Inc. (SPRO)
Proxy statement
Start not stated–2021-07-06
Last confirmed by a filing; no departure on record
Company network
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2020 | Spero Therapeutics, Inc. (SPRO) | Chief Medical Officer | $411,450 | $999,913 |
| 2019 | Spero Therapeutics, Inc. (SPRO) | Chief Medical Officer | $389,167 | $939,789 |
| 2018 | Spero Therapeutics, Inc. (SPRO) | Chief Medical Officer | $375,680 | $1,634,361 |